Enabling next-generation biologic delivery for pharmaceutical partners

HEED® (High Efficiency Elastomer Diaphragm) is a wearable delivery platform designed to support licensing and co-development of large-volume subcutaneous biologic therapies. The system enables transition from clinic-based infusion to controlled, patient-centric delivery.

KEY DIFFERENTIATOR

Advanced delivery architecture

  • Integrated sensing for pressure and flow behaviour

  • Electrolysis-driven pressure generation

  • Closed-loop delivery control system

  • Simplified, low-complexity actuation

A controlled delivery platform for next-generation biologics

HEED® integrates elastomer-based actuation, sensor feedback, and embedded control into a compact wearable system. This architecture delivers consistent performance while maintaining simplicity, scalability, and partner-ready integration.

Core Technology

  • Elastomer diaphragm delivery system

  • Electrolysis-based pressure generation

  • Integrated sensors (pressure, flow, tissue response)

  • Embedded control system for regulated delivery

HEED® Platform Modules

HEEDGUARD
Accurate, controlled delivery performance

HEEDHEALTH
Connected healthcare integration and monitoring

HEEDDOT
Low-volume precision delivery (3–5 mL)

HEEDMAX
Large-volume delivery capability (20–60 mL+)

System Intelligence

  • Real-time monitoring of delivery conditions

  • Closed-loop control for consistent dosing

  • Adaptive response to flow and resistance changes

PATIENT + THERAPY

Designed for:

  • Biologics and monoclonal antibodies

  • Immunotherapies

  • Chronic disease treatment

  • Ambulatory and home-based care

Why HEED®

Precision Dosing
Sensor-driven, controlled dosing performance

Build to Scale

Designed for licensing and co-development

Simplified Delivery
Simplified system vs traditional pump technologies

Designed for Patients
Enables transition to at-home treatment